

DAFTAR PUSTAKA

- Anwar, S. L., Cahyono, R., Avanti, W. S., Budiman, H. Y., Harahap, W. A., & Aryandono, T. (2021). Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression: A retrospective cohort study. *Annals of medicine and surgery (2021)*, *63*, 102144. <https://doi.org/10.1016/j.amsu.2021.01.092>
- Berger, D(1999). A brief history of medical diagnosis and the birth of the clinical laboratory *Part 1—Ancient times through the 19th century*. MLO. 1999;31(7):28-40 .[online](accessed: 16/05/2020)
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, *68*: 394-424. doi:10.3322/caac.21492
- Chen, Y., Chen, K., Xiao, X. et al. (2016). Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. *BMC Cancer* *16*, 320. <https://doi.org/10.1186/s12885-016-2352-8>
- Corbeau, I., Jacot, W., & Guiu, S. (2020). Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review. *Cancers*, *12*(4), 958. <https://doi.org/10.3390/cancers12040958>
- Engstrøm MJ1, Opdahl S, Hagen AI, et al.(2013).Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. *Breast Cancer Res Treat* ;140:463–73.
- Eroles, P.; Bosch, A.; Pérez-Fidalgo, J.A.; Lluch, A. (2012) Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. *Cancer Treat. Rev.* *38*, 698–707.
- Ethier, J., Desautels, D., Templeton, A. et al. (2017). Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. *Breast Cancer Res* *19*, 2 <https://doi.org/10.1186/s13058-016-0794-1>
- Faria, SS., Fernandes, P.C, Jr, Silva, M. J., Lima, VC, Fontes, W, Freitas-Junior, R, Eterovic, AK, & Forget, P (2016). The neutrophil-to-lymphocyte ratio: a

- narrative review. *Ecancermedicalsecience*, 10, 702.
<https://doi.org/10.3332/ecancer.2016.702>
- Gago-Dominguez, M., Matabuena, M., Redondo, C.M. et al. (2020). Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions. *Sci Rep* 10, 13203 <https://doi.org/10.1038/s41598-020-70077-z>
- Geng, S. K., Fu, S. M., Fu, Y. P., & Zhang, H. W. (2018). Neutrophil to lymphocyte ratio is a prognostic factor for disease free survival in patients with breast cancer underwent curative resection. *Medicine*, 97(35), e11898. <https://doi.org/10.1097/MD.00000000000011898>
- Goldszmid, R. S., Dzutsev, A., & Trinchieri, G. (2014). Host immune response to infection and cancer: unexpected commonalities. *Cell host & microbe*, 15(3), 295–305. <https://doi.org/10.1016/j.chom.2014.02.003>
- Green, S., Crowley, J., & Smith, A. (2010). *Clinical trials in oncology*. Chapman and Hall/CRC.
- Greten F.R., Grivennikov S.I. (2019). Inflammation and Cancer: Triggers, Mechanisms, and Consequences. *Immunity*. 51:27–41. doi: 10.1016/j.immuni.2019.06.025.
- Grivennikov S.I., Greten F.R., Karin M. (2010) Immunity, Inflammation, and Cancer. *Cell*. 140:883–899. doi: 10.1016/j.cell.2010.01.025.
- Gutman SI, Piper M, Grant MD, et al. (2013) Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? [Internet] Rockville (MD): Agency for Healthcare Research and Quality (US); Apr. Background. Available <https://www.ncbi.nlm.nih.gov/books/NBK137763/>
- Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J. A., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., & Zujewski, J. A. (2007). Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 25(15), 2127–2132. <https://doi.org/10.1200/JCO.2006.10.3523>
- Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L et al (2006) The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genom* 7:96

- Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O. (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. *Breast Cancer Res Treat.* Jun;139(2):539-52. doi: 10.1007/s10549-013-2560-8. Epub 2013 May 16. PMID: 23674192; PMCID: PMC3669503.
- Jingming, Y, Wang, W, Xu, L, Duan, X, Cheng, Y, Xin, L *et al.* (2017). A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer. *Chinese Journal of Cancer Research.* 29. 351-360. 10.21147/j.issn.1000-9604.2017.04.08.
- Junwu Duan, BS, Linlin Pan, MM, Ming Yang, MD (2018). Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer A meta-analysis. *Medicine (97:49)(e13340)*
- Kleinberg D L, Ruan W. (2008).IGF-I, GH, and sex steroid effects in normal mammary gland development. *J Mammary Gland Biol Neoplasia.* ;13(4):353–360.
- Lee, YM., Oh, M.H., Go, JH. *et al.*(2020). Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication. *Genes Genom* 42, 1381–1387 <https://doi.org/10.1007/s13258-020-01014-7>
- Li X., Dai D., Chen B., Tang H., Xie X., Wei W. (2018). The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. *J. Cancer.*9:861–871. doi: 10.7150/jca.23367.
- Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. (2021). Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. *Cancers (Basel).* Aug 25;13(17):4287. doi: 10.3390/cancers13174287. PMID: 34503097; PMCID: PMC8428369.
- MacEwan, J. P., Doctor, J., Mulligan, K., May, S. G., Batt, K., Zacker, C., Lakdawalla, D., & Goldman, D. (2019). The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers. *MDM policy & practice,* 4(1), 2381468319855386.

<https://doi.org/10.1177/2381468319855386>

- Okuturlar Y, Gunaldi M, Tiken EE, Oztosun B, Inan YO, Ercan T, Tuna S, Kaya AO, Harmankaya O, Kumbasar A. (2015). Utility of peripheral blood parameters in predicting breast cancer risk. *Asian Pac J Cancer Prev.* 2015;16(6):2409-12. doi: 10.7314/apjcp.16.6.2409. PMID: 25824773.
- Park YH, Senkus-Konefka E, Im SA, Pentheroudakis G, Saji S, Gupta S, *et al.* (2020). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. *Ann Oncol.* Apr;31(4):451-469. doi: 10.1016/j.annonc.2020.01.008. Epub 2020 Jan 16. PMID: 32081575.
- Pazdur R. (2008). Endpoints for assessing drug activity in clinical trials. *The oncologist*, 13 Suppl 2, 19–21. <https://doi.org/10.1634/theoncologist.13-S2-19>
- Raj-Kumar, P.-K.; Liu, J.; Hooke, J.A.; Kovatich, A.J.; Kvecher, L.; Shriver, C.D.; Hu, H. (2019). PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. *Sci. Rep.* , 9, 7956.
- Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Puzstai L, Bloom KJ. (2003). The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. *Oncologist.* 8(4):307-25. doi: 10.1634/theoncologist.8-4-307. PMID: 12897328.
- Saad ED, Katz A. (2009) Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. *Ann Oncol.* Mar;20(3):460-4. doi: 10.1093/annonc/mdn670. Epub 2008 Dec 18. PMID: 19095776.
- Saadatmand S, Bretveld R and Siesling S *et al* (2015) Influence of tumor stage at breast cancer detection on survival in modern times: population based study in 173797 patients *BMJ* 351 h4901 DOI: 10.1136/bmj.h4901
- Skandalakis J. (2009) Embryology and Anatomy of the Breast. In: Shiffman M. (eds) Breast Augmentation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78948-2_1

- Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci USA* 100:8418–8423
- Sun SX, Bostanci Z, Kass RB, Mancino AT, Kirby AL, Bland I, Copeland EM, Klimberg VS, Gradishar WJ. (2018) *The Breast (Fifth Edition)*, Elsevier, Pages 37-56.e6
- Sun YS, Zhao Z, Yang ZN, et al. (2017). Risk Factors and Preventions of Breast Cancer. *Int J Biol Sci.* 13(11):1387-1397. Published 2017 Nov 1. doi:10.7150/ijbs.21635
- Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst.* May 29;106(6):dju124. doi: 10.1093/jnci/dju124. PMID: 24875653.
- Vano YA, Oudard S, By MA, Têtu P, Thibault C, Aboudagga H, Scotté F, Elaidi R. (2018) Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. *PLoS One.* Apr 6;13(4):e0195042. doi: 10.1371/journal.pone.0195042. PMID: 29624591; PMCID: PMC5889159.
- WHO (2014) Early Stage Breast Cancer. Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines
- Wu, L., Saxena, S., Awaji, M., & Singh, R. K. (2019). Tumor-Associated Neutrophils in Cancer: Going Pro. *Cancers*, 11(4), 564. <https://doi.org/10.3390/cancers11040564>
- Xue L.B., Liu Y.H., Zhang B., Yang Y.F., Yang D., Zhang L.W., Jin J., Li J. (2019). Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis. *Medicine (Baltimore)* 98:e13842. doi: 10.1097/MD.00000000000013842.
- Yager JD, Davidson NE. (2006). Estrogen carcinogenesis in breast cancer. *N Engl J Med.* Jan 19;354(3):270-82. doi: 10.1056/NEJMra050776. PMID: 16421368.
- Yede, Jetendra et al. (2015) Clinical presentation, imaging, pathological profile and management of benign breast conditions based on aberrations of normal development and involution classification: A prospective cohort

study. *International Journal of Biomedical and Advance Research* 6 : 137-144.